On December 10, 2021, the Company announced its commitment to a plan to wind down the Company’s immuno-oncology program for cavrotolimod (AST-008) and the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia. The Company intends to realign its research and development resources to support (i) the development of its preclinical program targeting SCN9A for neuropathic pain, (ii) the continued advancement of its partnered programs with Ipsen Biopharm Limited to develop SNA-based treatments in neuroscience targeting Huntington’s disease and Angelman syndrome, (iii) its continued advancement of its partnered program with AbbVie to develop SNA-based treatments for hair loss disorders, as well as (iv) the continued research and development of other undisclosed therapeutic product candidates.
Recent XCUR News
- Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K • Business Wire • 04/22/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 05:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:36:01 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:37:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:16:37 PM
- Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis • Business Wire • 02/05/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:16:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 11:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 09:21:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:19:44 PM
- Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q • Business Wire • 11/28/2023 09:01:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:28:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:03:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 09:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 09:03:38 PM
- Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors • Business Wire • 08/23/2023 01:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 01:29:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/18/2023 10:09:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:33:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:18:03 PM
- Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Business Wire • 08/11/2023 08:01:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM